2024 HIV Prevention Drug Chart

Pre-Exposure Prophylaxis (PrEP)

PrEP is antiretroviral medication taken by a person who is HIV negative to reduce the risk of contracting HIV. The Food and Drug Administration has approved the following three regimens for PrEP:

DRUG	ADULT DOSING INFO	APPROVED FOR	DRUG CLASS
Truvada (tenofovir disoproxil fumarate + emtricitabine)	One tablet once a day. For some people, taking PrEP “on demand” before and after sex may be an option. Each tablet contains 300 mg tenofovir disoproxil fumarate (TDF) + 200 mg emtricitabine.	Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV. Generic version available.	Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs, or nukes)
Descovy (tenofovir alafenamide fumarate + emtricitabine)	One tablet once a day. Each tablet contains 25 mg tenofovir alafenamide fumarate (TAF) + 200 mg emtricitabine.	Not approved for those at risk for HIV acquisition via vaginal sex.	Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs, or nukes)
Apretude (cabotegravir)	Apretude is given as a single injection in the buttocks by a health care worker every other month. Apretude is initiated with two 600 mg injections given one month apart for the first two months, after which injections are given every two months. Alternatively, oral cabotegravir (Vocabria) may be taken for four weeks before the injections.	Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV.	Integrase Inhibitors

DRUG: Truvada (tenofovir disoproxil fumarate + emtricitabine)
ADULT DOSING INFO	One tablet once a day. For some people, taking PrEP “on demand” before and after sex may be an option. Each tablet contains 300 mg tenofovir disoproxil fumarate (TDF) + 200 mg emtricitabine.
APPROVED FOR	Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV. Generic version available.
DRUG CLASS	Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs, or nukes)

DRUG: Descovy (tenofovir alafenamide fumarate + emtricitabine)
ADULT DOSING INFO	One tablet once a day. Each tablet contains 25 mg tenofovir alafenamide fumarate (TAF) + 200 mg emtricitabine.
APPROVED FOR	Not approved for those at risk for HIV acquisition via vaginal sex.
DRUG CLASS	Nucleoside/ Nucleotide Reverse Transcriptase Inhibitors (NRTIs, or nukes)

DRUG: Apretude (cabotegravir)
ADULT DOSING INFO	Apretude is given as a single injection in the buttocks by a health care worker every other month. Apretude is initiated with two 600 mg injections given one month apart for the first two months, after which injections are given every two months. Alternatively, oral cabotegravir (Vocabria) may be taken for four weeks before the injections.
APPROVED FOR	Approved for HIV-negative men, women and transgender individuals at risk for sexually acquired HIV.
DRUG CLASS	Integrase Inhibitors

Post-Exposure Prophylaxis (PEP)

PEP involves taking a short course of antiretroviral drugs, usually for a month, after a high-risk exposure to HIV. For maximum effectiveness, PEP should be started immediately—and no more than 72 hours—after possible exposure. The Centers for Disease Control and Prevention (CDC) recommends the following preferred HIV PEP regimen:

DRUG	DOSING INFO
Isentress (raltegravir)	One tablet twice a day. Each tablet contains 400 mg of raltegravir.

DRUG: Isentress (raltegravir)
DOSING INFO	One tablet twice a day. Each tablet contains 400 mg of raltegravir.

PLUS

DRUG	DOSING INFO
Truvada (tenofovir disoproxil fumarate + emtricitabine)	One tablet once a day. Each tablet contains 300 mg tenofovir disoproxil fumarate + 200 mg emtricitabine.